RE:RE:RE:RE:RE:RE:RE:FirstStarkicker wrote: I agree there is potential, whether realized or not. However, when the CEO complains the SP is undervalued but offers no guidance or reasons to help improve it, it tells me there is no catalyst at the present time. I hope for all shareholders that have been so patient that something triggers a rise in SP soon.
Agreed fully. The CEO calling out the weakness and then saying nothing more in that call or the subsequent Q call is not acceptable. It comes across as whining and not having an action plan to address.
Certainly if all that they're expecting is that the SP will rise because of whatever they have cooking now, then that faith is looking misplaced. US rescheduling didn't so squat. Brazil announcement, similar squat. Germany announcement, super squat.
I have had full faith in Pidduck and Hunter as they have earned it. But if they fail to address these fundamental issues on the Q2 call and merely defer discussion, again, then I won't be happy. We've heard empty promises of growth for many Qs now, and my expectation is that the groundwork that has been long laid, starts impacting the business in a positive and material way. If Germany is exploding, then how in the hell can't LABS be taking part in that?
Am I bored, yes. Is it summer, yes. But with all of the activity in the sector, there has to be something LABS is working on that can provide shareholders with some love. A buyback say. Remidose is not the answer.